An immunotherapy clinical trial based in Seattle, among other U.S. sites, was pivotal to the Dec.
Frisco, Texas, resident Steve Murphy, 66, was diagnosed last September with Merkel cell carcinoma, a rare skin cancer he’d never heard of. His grim prognosis: 50 percent chance of surviving 90 days.
The number of U.S. cases of Merkel cell carcinoma, an often-fatal skin cancer, is rising about six times faster than most other cancers and at nearly twice the rate of the more-common melanoma.
Many patients with advanced Merkel cell carcinoma who received the immunotherapeutic pembrolizumab as first-line therapy in a